HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a $50 price target.
August 07, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sage Therapeutics' stock rating has been reiterated as Neutral by HC Wainwright & Co. with a maintained price target of $50.
The reiteration of a Neutral rating indicates that the analyst sees the stock as fairly valued at current levels. The maintained price target of $50 suggests that the analyst does not expect significant price movement in the short term. This could lead to a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100